STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Neurocrine Biosciences (NBIX) CSO details RSU vesting and 2,248 shares withheld for taxes

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Scientific Officer reports RSU vesting and tax withholding shares

The Chief Scientific Officer of Neurocrine Biosciences, Inc. reported routine equity activity on November 29, 2025. A restricted stock unit (RSU) award converted into 4,426 shares of common stock at an exercise price of $0, increasing the executive’s directly held position to 18,129 shares before tax withholding. To cover tax obligations on the RSU vesting, the company withheld 2,248 shares at a value of $152.16 per share, leaving the executive with 15,881 shares of common stock held directly after the transactions.

The RSU was originally granted on November 29, 2021 and vested in four annual tranches: 4,425 shares on November 29, 2022, 4,425 shares on November 29, 2023, 4,426 shares on November 29, 2024, and 4,426 shares on November 29, 2025, in each case subject to the award’s terms and conditions.

Positive

  • None.

Negative

  • None.
Insider Onyia Jude
Role Chief Scientific Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 4,426 $0.00 --
Exercise Common Stock 4,426 $0.00 --
Tax Withholding Common Stock 2,248 $152.16 $342K
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 18,129 shares (Direct)
Footnotes (1)
  1. Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Onyia Jude
(Last) (First) (Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/29/2025 M 4,426 A $0 18,129 D
Common Stock 11/29/2025 F 2,248(1) D $152.16 15,881 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 11/29/2025 M 4,426 (3) (3) Common Stock 4,426 $0 0 D
Explanation of Responses:
1. Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
2. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
3. This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact 12/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Neurocrine Biosciences (NBIX) report?

The Chief Scientific Officer reported the vesting of a restricted stock unit award that delivered 4,426 shares of Neurocrine Biosciences common stock on November 29, 2025.

How many Neurocrine Biosciences (NBIX) shares did the officer own after the reported transactions?

After the RSU vesting and related tax withholding, the officer beneficially owned 15,881 shares of Neurocrine Biosciences common stock in direct ownership.

Why were 2,248 Neurocrine Biosciences (NBIX) shares marked as disposed of?

The 2,248 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements upon RSU vesting; the filing notes that no shares were sold.

What was the value used for the withheld NBIX shares for tax purposes?

The shares withheld to cover taxes were valued at $152.16 per share, according to the reported transaction details.

What is the vesting schedule of the reported RSU grant at Neurocrine Biosciences (NBIX)?

The RSU grant dated November 29, 2021 vested as follows: 4,425 shares on November 29, 2022; 4,425 shares on November 29, 2023; 4,426 shares on November 29, 2024; and 4,426 shares on November 29, 2025, subject to the award terms.

What role does the reporting person hold at Neurocrine Biosciences (NBIX)?

The reporting person is an officer of Neurocrine Biosciences, serving as the company’s Chief Scientific Officer.